A Multi-center, Randomized, Double-blind, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia
Latest Information Update: 09 May 2025
At a glance
- Drugs JW-0108/C-2407 (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors JW Pharmaceutical
Most Recent Events
- 09 May 2025 New trial record